Literature DB >> 16178016

No increase of calcitonin gene-related peptide in jugular blood during migraine.

Jesper Filtenborg Tvedskov1, Kerstin Lipka, Messoud Ashina, Helle K Iversen, Søren Schifter, Jes Olesen.   

Abstract

Increased calcitonin gene-related peptide (CGRP) in external jugular venous blood during migraine attack is one of the most cited findings in the headache literature. The finding has not been convincingly reproduced and is based on comparison with historic control subjects. The validity of this finding is important for the understanding of migraine. We therefore investigated the issue using an intrapatient comparison design and two different CGRP assays. We sampled blood from the external jugular and cubital vein during, as well as outside of, an attack of migraine without aura. We succeeded in 17 patients, whereas only cubital fossa blood could be sampled in an additional 4 patients. CGRP was measured with the same assay as most previous studies (assay I) and furthermore with a more sensitive and validated assay (assay II). For assay I, mean CGRP concentration in external jugular venous blood during attack was 17.18 pmol/L compared with 15.88 pmol/L outside of attack. Mean difference was 1.81 pmol/L (95% confidence interval [CI]: -2.88, 6.41; p = 0.44). In peripheral blood during attack, CGRP was 16.86 pmol/L compared with 17.57 pmol/L outside of attack. Mean difference was -0.79 pmol/L (95% CI: -4.64, 3.06; p = 0.69). For assay II, external jugular venous blood concentration of CGRP during attack was 32.59 pmol/L compared with 30.59 pmol/L outside of attack; mean difference was 2.00 pmol/L (standard error, 2.39; 95% CI: -3.07, 7.07; p = 0.416). In peripheral blood during attack, CGRP was 33.37 pmol/L compared with 31.84 pmol/L outside of attack; mean difference was 1.53 pmol/L (standard error, 1.90; 95% CI: -2.46, 5.51; p = 0.431). Thus, no difference between CGRP level in external jugular or cubital fossa blood during and outside of attack was found. No difference was found between external jugular and peripheral venous blood. Thus, previous findings of increased CGRP level in external jugular or cubital fossa venous blood could not be confirmed. Our finding strongly suggests that CGRP is not increased in jugular venous blood during migraine without aura. CGRP cannot be used as a biomarker to validate human or animal models of migraine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178016     DOI: 10.1002/ana.20605

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  46 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 3.  Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine.

Authors:  Paul L Durham
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

Review 4.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 5.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 6.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

7.  Randomized, controlled trial of telcagepant for the acute treatment of migraine.

Authors:  K M Connor; R E Shapiro; H-C Diener; S Lucas; J Kost; X Fan; K Fei; C Assaid; C Lines; Tony W Ho
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

Review 8.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

9.  Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice.

Authors:  Blanca Marquez de Prado; Donna L Hammond; Andrew F Russo
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

10.  Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period.

Authors:  Ravi Gupta; Tanzeel Ahmed; Basudeb Banerjee; Manjeet Bhatia
Journal:  J Headache Pain       Date:  2009-03-11       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.